Cliff Asness's UTHR Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 986,478 shares of United Therapeutics Corporation (UTHR) worth $413.54 M, representing 0.27% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in UTHR, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2015, adding 485,617 shares. Largest reduction occurred in Q2 2019, reducing 1.36 M shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's United Therapeutics Corporation (UTHR) Holding Value Over Time
Track share changes against reported price movement
Quarterly United Therapeutics Corporation (UTHR) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2012 | +138,164 | Add 0.00% | 138,163 | $53.42 |
| Q2 2013 | +190,213 | Add 0.00% | 190,212 | $65.82 |
| Q3 2013 | -14,728 | Reduce 7.74% | 175,484 | $78.85 |
| Q4 2013 | +91,449 | Add 52.11% | 266,933 | $113.08 |
| Q1 2014 | +143,911 | Add 53.91% | 410,844 | $94.03 |
| Q2 2014 | +103,000 | Add 25.07% | 513,844 | $88.49 |
| Q3 2014 | +35,200 | Add 6.85% | 549,044 | $128.65 |
| Q4 2014 | +322,511 | Add 58.74% | 871,555 | $129.49 |
| Q1 2015 | -70,166 | Reduce 8.05% | 801,389 | $172.43 |
| Q2 2015 | +54,920 | Add 6.85% | 856,309 | $173.95 |
| Q3 2015 | +446,846 | Add 52.18% | 1.3 M | $131.24 |
| Q4 2015 | +485,617 | Add 37.26% | 1.79 M | $156.61 |
| Q1 2016 | -481,925 | Reduce 26.94% | 1.31 M | $111.43 |
| Q2 2016 | +277,266 | Add 21.22% | 1.58 M | $105.92 |
| Q3 2016 | -256 | Reduce 0.02% | 1.58 M | $118.08 |
| Q4 2016 | -224,895 | Reduce 14.20% | 1.36 M | $143.43 |
| Q1 2017 | +377,395 | Add 27.77% | 1.74 M | $135.38 |
| Q2 2017 | +452,844 | Add 26.08% | 2.19 M | $129.73 |
| Q3 2017 | -9,201 | Reduce 0.42% | 2.18 M | $118.53 |
| Q4 2017 | -246,958 | Reduce 11.33% | 1.93 M | $147.95 |
| Q1 2018 | -110,571 | Reduce 5.72% | 1.82 M | $112.36 |
| Q2 2018 | +269,437 | Add 14.78% | 2.09 M | $113.49 |
| Q3 2018 | +235,459 | Add 11.26% | 2.33 M | $127.88 |
| Q4 2018 | +187,196 | Add 8.04% | 2.51 M | $108.90 |
| Q1 2019 | -25,345 | Reduce 1.01% | 2.49 M | $117.37 |
| Q2 2019 | -1.36 M | Reduce 54.56% | 1.13 M | $77.46 |
| Q3 2019 | -593,931 | Reduce 52.51% | 537,213 | $79.75 |
| Q4 2019 | +133,916 | Add 24.93% | 671,129 | $87.33 |
| Q1 2020 | +203,177 | Add 30.27% | 874,306 | $94.82 |
| Q2 2020 | +57,566 | Add 6.58% | 931,872 | $120.82 |
| Q3 2020 | +11,178 | Add 1.20% | 943,050 | $101.00 |
| Q4 2020 | -318,854 | Reduce 33.81% | 624,196 | $151.79 |
| Q1 2021 | +3,071 | Add 0.49% | 627,267 | $167.27 |
| Q2 2021 | -120,489 | Reduce 19.21% | 506,778 | $176.88 |
| Q3 2021 | -55,171 | Reduce 10.89% | 451,607 | $184.58 |
| Q4 2021 | -49,571 | Reduce 10.98% | 402,036 | $216.08 |
| Q1 2022 | -25,645 | Reduce 6.38% | 376,391 | $175.58 |
| Q2 2022 | -23,313 | Reduce 6.19% | 353,078 | $235.64 |
| Q3 2022 | -58,990 | Reduce 16.71% | 294,088 | $208.57 |
| Q4 2022 | -34,079 | Reduce 11.59% | 260,009 | $274.13 |
| Q1 2023 | +113,214 | Add 43.54% | 373,223 | $220.72 |
| Q2 2023 | +137,378 | Add 36.81% | 510,601 | $219.00 |
| Q3 2023 | -34,013 | Reduce 6.66% | 476,588 | $225.86 |
| Q4 2023 | +75,179 | Add 15.77% | 551,767 | $218.79 |
| Q1 2024 | +295,188 | Add 53.50% | 846,955 | $229.72 |
| Q2 2024 | -127,445 | Reduce 15.05% | 719,510 | $318.55 |
| Q3 2024 | +248,224 | Add 34.50% | 967,734 | $358.35 |
| Q4 2024 | +7,710 | Add 0.80% | 975,444 | $352.84 |
| Q1 2025 | -66,996 | Reduce 6.87% | 908,448 | $300.85 |
| Q2 2025 | +364,713 | Add 40.15% | 1.27 M | $285.02 |
| Q3 2025 | -286,683 | Reduce 22.52% | 986,478 | $419.21 |
Cliff Asness's United Therapeutics Corporation Investment FAQs
Cliff Asness first purchased United Therapeutics Corporation (UTHR) in Q4 2012, acquiring 138,163 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held United Therapeutics Corporation (UTHR) for 52 quarters since Q4 2012. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to United Therapeutics Corporation (UTHR) was in Q4 2015, adding 1,788,772 shares worth $280.14 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 986,478 shares of United Therapeutics Corporation (UTHR), valued at approximately $413.54 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, United Therapeutics Corporation (UTHR) represents approximately 0.27% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in United Therapeutics Corporation (UTHR) was 2,514,563 shares, as reported at the end of Q4 2018. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.